Last mentioned: Mar 26, 2026
Q1 Guidance
Precigen forecasts $18M+ revenue for Q1 2026, a massive sequential jump.
Paysign 2026 Outlook
Paysign projects 30-35% revenue growth for the coming fiscal year.
Recombinant Albumin Launch
Dyadic and ProLiant initiate commercial launch of recombinant albumin.
Albumin Commercialization
Dyadic and ProLiant Health launch recombinant albumin for global sales.
Dyadic Year-End Cash
Dyadic ends fiscal year with $8.6 million in cash and liquid assets.
FY 2025 Close
Dyadic ends year with $8.6M cash; Paysign hits record $82M annual revenue.
Precigen Commercial Launch
Initial commercial shipments of Papzimius for adult RRP begin.
Papzimius Launch
Precigen initiates commercial shipments of Papzimius for adult RRP.
Dyadic and Precigen have successfully transitioned from R&D-focused entities to commercial-stage biotechs, marked by the launch of recombinant albumin and Papzimius respectively. This shift is supported by a robust pharma services sector, as evidenced by Paysign’s record growth in patient affordability programs for top-tier manufacturers.
The Q4 2025 earnings cycle marks a critical transition for mid-cap biotech and health-IT firms as they shift from R&D-heavy profiles to commercial-stage entities. Key players like Dyadic and Precigen are reporting initial product revenues and expanded distribution networks, while service providers like Paysign see massive growth in patient affordability programs.